文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

转录组评分识别ICU获得性感染高风险且临床病程不良的危重患者亚组

Identification of a sub-group of critically ill patients with high risk of intensive care unit-acquired infections and poor clinical course using a transcriptomic score.
PubMed 文献 · Crit Care · 2023-04-21
一句话结论基于免疫相关基因的转录组评分(TScore)在危重患者中识别出ICU获得性感染高风险亚组(高风险组49% vs 低风险组4%),该组ICU住院时间更长、ICU死亡率更高。

研究利用REALISM研究(NCT02638779)中176例第5-7天仍在ICU的危重患者作为训练队列,基于每个免疫相关基因独立识别第5-7天后发生ICU获得性感染(ICU-AI)的表现,构建了假设各基因独立的非加权转录组评分(TScore)。TScore识别出高风险组(49%),其ICU-AI发生率较高风险组49% vs 低风险组4%,ICU住院时间13天(95%CI 8-30)vs 7天(95%CI 6-9),p<0.001,ICU死亡率15% vs 2%。高风险患者表现出免疫抑制的生物学特征:单核细胞HLA-DR水平低、未成熟中性粒细胞比例高、IL10浓度高。在257例脓毒症患者的回顾性验证队列中,TScore识别出160例高风险患者(62%),ICU-AI发生率30% vs 低风险组18%(p=0.06),且死亡率显著更高、ICU住院时间更长。

要点

  • TScore在训练队列中识别出49%的高风险患者,其ICU-AI发生率为49%,而低风险组仅4%。
  • 高风险组ICU住院时间13天(95%CI 8-30)vs 低风险组7天(95%CI 6-9),p<0.001;ICU死亡率15% vs 2%。
  • 高风险患者具有免疫抑制特征:单核细胞HLA-DR水平低、未成熟中性粒细胞比例高、IL10浓度高。
  • 在257例脓毒症患者的回顾性验证队列中,TScore识别出160例(62%)高风险患者,ICU-AI发生率30% vs 低风险组18%(p=0.06),且死亡率显著更高、ICU住院时间更长。

适用人群与场景

  • 训练队列为REALISM研究(NCT02638779)纳入的176例危重患者,病因多样,第5-7天仍在ICU住院。
  • 验证队列为257例脓毒症患者的回顾性队列。

诊断标准与关键阈值

  • 转录组评分(TScore)基于多个免疫相关基因表达量构建,假设各基因独立,为非加权评分;原文未给出具体基因列表及评分界值。

研究设计与关键结果

  • 训练队列中,TScore识别出高风险组(49%),其ICU-AI发生率为49%,低风险组为4%;高风险组ICU住院时间13天(95%CI 8-30)vs 低风险组7天(95%CI 6-9),p<0.001;ICU死亡率15% vs 2%。
  • 高风险患者表现出免疫抑制的生物学特征:单核细胞HLA-DR水平低、未成熟中性粒细胞比例高、IL10浓度高。
  • 验证队列中,TScore识别出160例高风险患者(62%),其ICU-AI发生率为30%,低风险组为18%(p=0.06),且死亡率显著更高、ICU住院时间更长。

证据类型、等级与局限

  • 证据类型:训练队列为REALISM研究(NCT02638779)的基因表达数据集分析,验证队列为257例脓毒症患者的回顾性队列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该转录组评分可作为有用的、可靠的伴随诊断工具,用于在个性化医疗背景下进一步开发脓毒症的免疫调节药物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The development of stratification tools based on the assessment of circulating mRNA of genes involved in the immune response is constrained by the heterogeneity of septic patients. The aim of this study is to develop a transcriptomic score based on a pragmatic combination of immune-related genes detected with a prototype multiplex PCR tool.

METHODS: As training cohort, we used the gene expression dataset obtained from 176 critically ill patients enrolled in the REALISM study (NCT02638779) with various etiologies and still hospitalized in intensive care unit (ICU) at day 5-7. Based on the performances of each gene taken independently to identify patients developing ICU-acquired infections (ICU-AI) after day 5-7, we built an unweighted score assuming the independence of each gene. We then determined the performances of this score to identify a subgroup of patients at high risk to develop ICU-AI, and both longer ICU length of stay and mortality of this high-risk group were assessed. Finally, we validated the effectiveness of this score in a retrospective cohort of 257 septic patients.

RESULTS: This transcriptomic score (TScore) enabled the identification of a high-risk group of patients (49%) with an increased rate of ICU-AI when compared to the low-risk group (49% vs. 4%, respectively), with longer ICU length of stay (13 days [95% CI 8-30] vs. 7 days [95% CI 6-9], p < 0.001) and higher ICU mortality (15% vs. 2%). High-risk patients exhibited biological features of immune suppression with low monocytic HLA-DR levels, higher immature neutrophils rates and higher IL10 concentrations. Using the TScore, we identified 160 high-risk patients (62%) in the validation cohort, with 30% of ICU-AI (vs. 18% in the low-risk group, p = 0.06), and significantly higher mortality and longer ICU length of stay.

CONCLUSIONS: The transcriptomic score provides a useful and reliable companion diagnostic tool to further develop immune modulating drugs in sepsis in the context of personalized medicine.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bodinier M, Monneret G, Casimir M, et al. Identification of a sub-group of critically ill patients with high risk of intensive care unit-acquired infections and poor clinical course using a transcriptomic score. Crit Care. 2023. PMID: 37085849. doi:10.1186/s13054-023-04436-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。